The absence of a 'relative vasopressin deficiency' may be one reason for the ineffectiveness of AVP in reducing norepinephrine requirements as compared with standard treatment with norepinephrine in the placebo group. Here, AVP is linked to neurohypophyseal diabetes insipidus.